Skip to content
ATLAS PREP HQ
Healing

Cartalax

Ala-Glu-Asp (AED) tripeptide bioregulator

Short peptide bioregulator studied for connective-tissue support and fibroblast-related activity.

Preclinical Evidence

Route

Subcutaneous in the community educational protocol

Common format

20 mg vial

Research focus

cartilage biology

Evidence level

Preclinical Evidence

Typical cycle

8–12 weeks

Healing research motifHealing

Cartalax in 30 seconds

Atlas Fast Read

What it is

Ala-Glu-Asp (AED) tripeptide bioregulator

Why people care

Short peptide bioregulator studied for connective-tissue support and fibroblast-related activity.

Human evidence

Preclinical Evidence — The exact compound or use is supported mainly by animal, in-vitro, or mechanistic work, or lacks meaningful controlled human efficacy evidence.

Biggest misconception

Key gaps include validated human dosing, pharmacokinetics, long-term safety, clinically meaningful efficacy, product standardization, and independent replication in well-controlled trials.

Bottom line

Cartalax is scientifically interesting for cartilage biology, fibroblast aging, but the current case is driven mainly by cell and animal data.

Overview

What is Cartalax?

Cartalax is ala-Glu-Asp (AED) tripeptide bioregulator. Short peptide bioregulator studied for connective-tissue support and fibroblast-related activity.

Developed within Vladimir Khavinson's short-peptide bioregulator program in St. Petersburg. Most of its literature comes from Russian gerontology, cell-culture, and connective-tissue research rather than large international clinical trials.

Mechanism

How it works

Proposed to modulate gene expression in fibroblasts and chondrocytes. Preclinical studies report changes in proliferation markers, sirtuins, apoptotic signaling, MMP-9, and extracellular-matrix regulation.

Research areas

cartilage biologyfibroblast agingextracellular matrixconnective-tissue repair

Evidence

What does the evidence actually say?

Preclinical Evidence

The exact compound or use is supported mainly by animal, in-vitro, or mechanistic work, or lacks meaningful controlled human efficacy evidence.

01

Preclinical Evidence

02

Limited Human Evidence

03

Strong Human Evidence

Human evidence

No large, independently replicated human trials establish Cartalax for osteoarthritis, cartilage repair, or connective-tissue rejuvenation. Human claims rely mainly on the broader peptide-bioregulator literature rather than modern controlled trials of Cartalax itself.

Preclinical evidence

Cell and animal studies report effects on fibroblast/chondrocyte proliferation, extracellular-matrix genes, oxidative stress, and age-related signaling. Independent replication outside the peptide-bioregulator literature is limited.

Knowledge gaps

Key gaps include validated human dosing, pharmacokinetics, long-term safety, clinically meaningful efficacy, product standardization, and independent replication in well-controlled trials.

Protocol

Research protocol

DoseFrequencyTimingCycle

Dose

Community research reference: 2–5 mg/day with titration. No validated human SC dose exists.

Frequency

Once daily in the community protocol.

Timing

No established time-of-day requirement.

Route

Subcutaneous in the community educational protocol; route/dose are not supported by large human trials.

Cycle length

8–12 weeks

Reconstitution

Community reference: 2 mL bacteriostatic water per 20 mg vial = 10 mg/mL.

Storage

Community reference: lyophilized refrigerated or frozen; reconstituted 2–8 °C; avoid freeze-thaw.

Monitoring

No validated monitoring protocol. For joint/tissue research use objective pain/function measures; CBC/CMP are general safety markers rather than Cartalax-specific biomarkers.

Protocols vary widely between sources. Investigational compounds are not approved therapies, and approved products should follow their official labeling. Nothing here is medical advice.

Safety

Safety, side effects, and precautions

Side effects

Controlled human safety data are limited. Possible issues include injection-site reactions, headache, nausea, dizziness, fatigue and hypersensitivity. Because several proposed mechanisms involve angiogenesis or tissue-growth signaling, long-term systemic effects are uncertain.

Contraindications

No validated human contraindication profile exists. Pregnancy/breastfeeding, active malignancy, unexplained masses, major bleeding disorders or serious systemic illness warrant avoidance outside formal research/medical oversight.

Interactions

Formal interaction studies are lacking. Use with anticoagulants/antiplatelet drugs, growth-factor therapies, immunomodulators or other experimental repair peptides creates unknown additive risks.

Stacks

Common stacks

No well-supported stack is highlighted for this peptide yet.

Questions

FAQ

References

Sources

Atlas

The Atlas verdict

Cartalax is scientifically interesting for cartilage biology, fibroblast aging, but the current case is driven mainly by cell and animal data. Atlas would treat claimed benefits as hypotheses—not established human outcomes—and would put human safety, product quality, and controlled trials ahead of protocol optimization.

More in Healing

Healing

Ara-290

Innate-repair-receptor peptide research centered on inflammation, tissue protection, and neuropathy.

Read guide

Healing

BPC-157

Synthetic peptide studied primarily for tissue repair, cytoprotection, and gastrointestinal healing pathways.

Read guide

Healing

BPC-157 + TB-500

Combination research pairing BPC-157 and TB-500 for tissue repair, wound healing, and musculoskeletal recovery.

Read guide